Navigation Links
CT and serum LDH shows promise as survival predictor for some metastatic melanoma patients
Date:4/16/2013

Combining CT imaging findings with baseline serum lactate dehydrogenase levels is showing promise as a way to predict survival in patients with metastatic melanoma being treated with anti-angiogenic therapy.

With the hope of predicting patient survival, researchers at the University of Mississippi Medical Center in Jackson and at the Ohio State University Comprehensive Cancer Center in Columbus analyzed CT images and clinical data from 46 patients with metastatic melanoma that were treated with anti-angiogenic therapy. "The analysis found that initial post-therapy CT imaging changes in tumor morphology, attenuation, size and structure (MASS Criteria) are predictive of survival. These results are similar to what we have found in patients with metastatic kidney cancer, another highly vascular tumor treated with anti-angiogenic therapy. The current study is the first of its kind to associate CT findings of tumor devascularization with survival in patients with metastatic melanoma treated with anti-angiogenic therapy," said Dr. Andrew Smith of the University of Mississippi.

"Patients with high baseline serum lactate dehydrogenase (LDH) tend to have poor overall survival compared to patients with low serum LDH," said Dr. Smith. LDH levels are used to stage metastatic melanoma, but are only weakly associated with survival when used alone," he said. "What was surprising to us was that the accuracy for predicting both progression-free and overall survival is substantially increased when MASS Criteria findings are combined with data from serum LDH levels," said Dr. Smith.

"This was an exploratory study," said Dr. Smith. "The next step is to take what we've discovered and test it in prospective clinical trials. At a minimum, patients with low baseline serum LDH and evidence of tumor devascularization on their initial post-therapy CT should be encouraged that they are likely to have a favorable response to therapy," he said.

"Th
'/>"/>

Contact: Samantha Schmidt
sschmidt@arrs.org
703-858-4316
American Roentgen Ray Society
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Low levels of serum bilirubin spell higher lung cancer risk for male smokers
2. New - Renaissance Age Serum, a Revival in Swiss Anti-Aging Skin Care; Improve Skin Texture for a More Youthful Appearance using Gerda Spillmann’s Newest Anti-Aging Serum
3. Some minorities believe they are less likely to get cancer compared to whites, Moffitt study shows
4. Study shows severity of sleep apnea is influenced by race
5. Stanford study shows different brains have similar responses to music
6. 2-drug combo more effective in treating sarcomas, Moffitt Cancer Center study shows
7. Experimental Vaccine Shows Promise for Ovarian Cancer
8. 2-step ovarian cancer immunotherapy made from patients own tumor shows promise
9. CAMH study shows mental illness associated with heavy cannabis use
10. More Evidence Shows Hormone Therapy May Increase Breast Cancer Risk
11. New technique shows promise in restoring near vision without glasses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... ... The popular television program VOICES IN AMERICA, hosted by legendary star of ... an entire short segment to the subject of diabetes. Diabetes is a debilitating health ... basis, but recent advancements in medical science may prove to be a significant breakthrough ...
(Date:8/28/2015)... ... 2015 , ... An online provider of CPAP machines, masks, supplies, and accessories, ... more affordable by offering shipping at no cost to you, directly to your door ... any size. My Cpap Store is located in Las Vegas, Nevada. , Sleep apnea ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of furthering music education programs ... to the Adams County Fairgrounds in Mendon, IL on May 30th, 2015. Backed once ... music education in the underfunded school districts of Mendon and its neighboring town of ...
(Date:8/28/2015)... ... August 28, 2015 , ... The 6th Annual Survivor in ... Foundation has added yet another accolade to its cadre of widespread support—an official letter ... “With the help of the medical community and the University of Illinois at Chicago’s ...
(Date:8/28/2015)... ... August 28, 2015 , ... “ Frequentz ” was featured on NewsWatch as ... applications on the market for iOS, Android, and Windows. Joe Toohey, the host of ... software allows businesses to track product movement from beginning to end. , Businesses benefit ...
Breaking Medicine News(10 mins):Health News:My Cpap Store Now Offering Delivery Special 0 Cost to You 2Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2
... with diastolic blood pressure under 70 mm Hg coupled ... greater risk of heart attack and stroke than indicated ... a UC Irvine study. , Dr. Stanley Franklin and ... in conjunction with researchers at the Framingham Heart Study ...
... for February 19, 2009 at 10:30 am PT MISSION ... ENSG ), the parent company of the Ensign(TM) ... companies, today reported record results for the fourth quarter of ... Quarter Highlights Include: , , ...
... Puerto Rico transfer toxins into seafood, scientist says , , WEDNESDAY, ... leak cancer-causing toxins that are absorbed by marine life and ... warns. , "Unexploded bombs are in the ocean for ... not explode, others were dumped in the ocean as a ...
... accurate in early tests , , WEDNESDAY, Feb. 18 (HealthDay ... widely used anticoagulant warfarin safer by predicting the lowest ... Food and Drug Administration estimates that 2 million Americans ... can cause strokes. Reasons range from implantation of an ...
... Developed Health & Beauty Products for Pregnant Women Creates ... Hollywood,s baby boom in full-swing, Beaute de Maman ... products designed exclusively for the pregnant woman by an ... celebrity moms-to-be including actresses Penelope Ann Miller, Salli Richardson-Whitfield ...
... Westaim Corporation announced today that for the year ended December 31, ... cents per share, on revenues of $22.4 million compared to a ... revenues of $31.8 million in the previous year. For the three ... of $2.7 million, or 3 cents per share, compared to a ...
Cached Medicine News:Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 3Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 4Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 5Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 6Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 7Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 8Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 9Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 10Health News:The Ensign Group, Inc. Reports Fourth Quarter 2008 Earnings of $0.38 per Share; Issues 2009 Guidance 11Health News:Sunken, Unexploded Bombs Pose Cancer Risk 2Health News:Genetics May Help Fine-Tune Warfarin Dosage 2Health News:Genetics May Help Fine-Tune Warfarin Dosage 3Health News:Genetics May Help Fine-Tune Warfarin Dosage 4Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 2Health News:Hollywood's Celebrity Moms-To-Be Get Acquainted With All-Natural Beaute de Maman Product Line 3Health News:Westaim announces 2008 year-end results 2Health News:Westaim announces 2008 year-end results 3Health News:Westaim announces 2008 year-end results 4Health News:Westaim announces 2008 year-end results 5Health News:Westaim announces 2008 year-end results 6Health News:Westaim announces 2008 year-end results 7Health News:Westaim announces 2008 year-end results 8Health News:Westaim announces 2008 year-end results 9Health News:Westaim announces 2008 year-end results 10Health News:Westaim announces 2008 year-end results 11Health News:Westaim announces 2008 year-end results 12
(Date:8/28/2015)... -- The global mHealth market ... 2020, growing at a CAGR of 47.6% from 2013 ... View Research, Inc. Monitoring services is expected to grow ... 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... of chronic diseases such as cancer, heart ailments, and ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
Breaking Medicine Technology:mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2
... Cytogen,Corporation (NASDAQ: CYTO) reported updated data from ... (samarium Sm-153,lexidronam injection) in combination with bortezomib ... myeloma. Data from 33 patients were presented ... of Bortezomib (Vel) and Samarium,(Sam) in Multiple ...
... 100 percent response rate achieved with VELCADE, ... /PRNewswire-FirstCall/ -- Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM) today ... clinical trials of VELCADE based,therapies that showed ... response(1) (CR) rates in newly diagnosed,multiple myeloma ...
Cached Medicine Technology:Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 2Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 3Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 4Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 5Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 6Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 7Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Quadramet at International Myeloma Workshop 8Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 2Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 3Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 4Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 5Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 6Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 7Velcade (bortezomib) for Injection Based Therapies Achieved,Survival Rates as High as 100 Percent in Newly Diagnosed Multiple,Myeloma Patients 8
... A stethoscope adapter for users of ... acrylic shell type., ,Impressions of ... ,Westone custom products for the ear ... of hearing healthcare providers. These providers ...
Advanced architecture. Small, lightweight and compact. Easy to use....
... bronchoscopy: The HF-compatible V series from Pentax, ... bronchoscopes are measured., ,The HF-compatible series ... FB-19TV, FB-18V and FB-15V models along with ... FB-8V, offer much better image quality thanks ...
... benefits of fibre bronchoscopy: The HF-compatible V ... all other fibre bronchoscopes are measured., ... PENTAX, including the FB-19TV, FB-18V and FB-15V ... and the pediatric FB-8V, offer much better ...
Medicine Products: